FDA advisory committee says risks of Novo Nordisk’s once-weekly insulin...
An FDA advisory committee on Friday voted not to recommend Novo Nordisk’s once-weekly insulin injection in type 1 diabetes patients. Novo has pitched its candidate as a more convenient alternative to...
View ArticlePfizer's $1.5B cuts; Biogen's $1.15B buyout; AstraZeneca's $80B ambition; RNA...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Novartis to seek approvals in two rare kidney diseases after positive Phase 3...
Novartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the European Renal Association conference, touting positive results for an investigational drug in IgA...
View ArticleClik here to view.
After 14 years calling partnering shots at Genentech/Roche, James Sabry is...
Bioregnum Opinion Column by John Carroll James Sabry, the longtime doyen of biotech dealmakers from his global perch at Roche/Genentech, is jumping to the US biotech scene. The Basel-based pharma giant...
View ArticleBioNTech doubles down on ADC partner MediLink in new $1.8B biobucks pact
As BioNTech’s pipeline tilts back toward oncology, the German biotech is once again tapping a young Chinese partner in a bid for the next generation of the field’s hottest modality. It’s going back to...
View ArticleJapan’s Asahi Kasei offers to acquire Calliditas Therapeutics for $1B
A Japanese conglomerate is offering to buy Calliditas Therapeutics for more than $1 billion in a bid to enter a burgeoning autoimmune disease space. Three of Calliditas’ largest shareholders have...
View Article#ASCO24: Merus, touting more Phase 2 data, plots pivotal head and neck cancer...
Merus released additional head and neck cancer data from a Phase 2 study on Tuesday after publishing an ASCO abstract last week and outlined plans for a pivotal trial in the first-line setting. The...
View ArticleGilead forms pact with Cartography to map new targets for cancer drugs
Gilead will work with fellow California biotech Cartography Biosciences to find new targets for breast and lung cancer medicines, the companies said Tuesday morning. The deal includes $20 million...
View ArticleCorrected: AstraZeneca, Daiichi Sankyo’s TROP2 ADC boosts survival in Phase 3...
AstraZeneca and Daiichi Sankyo said their TROP2-directed antibody-drug conjugate met a primary survival endpoint in a key subset of patients in a late-stage lung cancer trial, despite a miss in the...
View ArticleNS Pharma's Duchenne muscular dystrophy drug Viltepso flunks Phase 3...
NS Pharma’s Duchenne muscular dystrophy drug Viltepso failed its confirmatory study. Despite the failure, the company is keeping faith in the drug and running further analyses to see if other factors...
View ArticleTakeda to lay off 640 workers in Massachusetts as part of multiyear overhaul
Takeda’s multiyear “efficiency program” is in full swing. The Japanese pharma is set to let go a total of 641 workers in Massachusetts: 495 in Cambridge and the remaining 146 in Lexington, a...
View ArticleClik here to view.
NewAmsterdam says former Amgen cardio drug reduces heart disease risk factor
A Dutch biotech has proved its resurrected Amgen drug is capable of significantly lowering “bad” cholesterol in a handful of mid-stage trials in recent years, and a new analysis suggests the therapy...
View ArticleJ&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey
Johnson & Johnson is spending $1.25 billion in cash to buy Yellow Jersey Therapeutics, marking its second acquisition in the burgeoning I&I field in as many weeks. J&J’s deal to buy Yellow...
View ArticleAgios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement
Plus, news about Turn Biotechnologies, HanAll Biopharma, Corcept Therapeutics, Actuate and Merck: Agios sells vorasidenib rights to Royalty Pharma: As part of the agreement, the biotech will get a $905...
View ArticleClik here to view.
Insmed stock skyrockets on Phase 3 lung disease data
Shares of Insmed $INSM more than doubled Tuesday morning after the company released Phase 3 data in a respiratory disease called bronchiectasis. The company’s drug, known as brensocatib, reduced...
View ArticleClik here to view.
FDA clears IND for Be Bio's engineered B cell therapy in hemophilia B
In a first, the FDA cleared a B cell therapy for clinical testing in hemophilia B in the latest step forward for a new approach to treating genetic disorders. Be Bio expects to begin dosing its...
View ArticleClik here to view.
Joe Panetta to step down as Biocom California CEO
Joe Panetta, who has led the trade group Biocom California for 25 years, is slated to step down as president and CEO at the end of the year, according to the organization. Tim Scott Panetta will be...
View ArticleLouisiana governor signs law limiting ability of doctors to prescribe...
Louisiana became the first state to enact a law that classifies the abortion-inducing drugs mifepristone and misoprostol as schedule IV drugs, meaning they are considered potentially dangerous and...
View ArticleClik here to view.
Canadian biotech VC Amplitude raises $192M second fund
Amplitude Ventures, a Montreal-based life sciences VC firm, has raised a second fund to deploy into 14 to 16 startups. Dion Madsen The $263 million CAD ($192 million) precision medicine fund has...
View ArticleClik here to view.
GLP-1 prescriptions reach all-time high as Lilly and Novo scramble to keep...
More US patients than ever are being prescribed GLP-1 weight loss medications each week, and biopharma experts have increased their annual sales forecasts of the drugs to more than $150 billion by...
View Article